Tango Therapeutics, Inc.
TNGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TNGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TNGX
Tango Therapeutics, Inc. is a clinical-stage precision oncology company developing novel therapies targeting cancer vulnerabilities, with no approved products or product revenue to date.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.94B
Cash Runway
76.2 moLead Asset
TNG260 (Phase 1/Phase 2)Next Catalyst
Phase3_Topline · Aug 31, 2029Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 8 clinical trials · 1 catalyst for Tango Therapeutics, Inc..
Tango Therapeutics, Inc. is a clinical-stage precision oncology company developing novel therapies targeting cancer vulnerabilities, with no approved products or product revenue to date.
- Tango Therapeutics has no approved products and has never generated revenue from product sales [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company reported cash, cash equivalents, and marketable securities of $1.0 billion [sec_mda · as of 2026-08-11].
- For the six months ended June 30, 2026, net loss was $100.9 million, and accumulated deficit reached $704.0 million [sec_mda · as of 2026-08-11].
- The company is enrolling patients in multiple Phase 1/2 clinical trials evaluating safety and efficacy in various indications [sec_mda · as of 2026-03-05].
- Tango has raised $1.2 billion in aggregate from equity financings and its collaboration with Gilead through March 31, 2026 [sec_mda · as of 2026-05-13].
What works
- Cash position of $1.0 billion as of June 30, 2026 provides runway for at least twelve months from the issuance of the financial statements [sec_mda · as of 2026-08-11].
- Multiple Phase 1/2 clinical trials are ongoing, with several programs in dose escalation and expansion stages [sec_mda · as of 2026-03-05].
- The company has a collaboration with Gilead that contributed $237.1 million in funding through August 2025 [sec_mda · as of 2026-08-11].
What to weigh
- The company has no approved products and has never generated product revenue; future revenue depends on successful clinical development and regulatory approval [sec_mda · as of 2026-08-11].
- Net losses are increasing: $100.9 million for the six months ended June 30, 2026 vs. $78.7 million for the same period in 2025 [sec_mda · as of 2026-08-11].
- Accumulated deficit was $704.0 million as of June 30, 2026, reflecting significant historical operating losses [sec_mda · as of 2026-08-11].
- The company expects expenses to increase substantially as clinical trials advance, including pivotal trials [sec_mda · as of 2026-03-05].
From the filings
Quoted directly from source documents.
No product revenue to date
“We do not have any product candidates approved for sale and have not generated any revenue from product sales.”
SEC MD&A · August 11, 2026
Cash position as of June 30, 2026
“We expect that our existing cash, cash equivalents and marketable securities on hand as of June 30, 2026 of $1.0 billion, will enable us to meet our current operating plan”
SEC MD&A · August 11, 2026
Net loss for six months ended June 30, 2026
“For the six months ended June 30, 2026 and 2025, our net losses were $100.9 million and $78.7 million, respectively.”
SEC MD&A · August 11, 2026
Accumulated deficit as of June 30, 2026
“We had an accumulated deficit of $704.0 mi”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2029-08-31 · Phase3_Topline · mfolfirinox — Phase 3 Topline — A Phase 3, double-blind, placebo-controlled, randomized study to assess efficacy and safety of a Tango candidate in combination with mfolfirinox.
Risks & what to watch (4)›
Key risks
- No approved products — No product candidates approved; no product revenue generated. Future revenue depends on successful development and approval [sec_mda · as of 2026-08-11].
- Increasing net losses — Net loss grew to $100.9M for H1 2026 from $78.7M in H1 2025, with accumulated deficit of $704.0M [sec_mda · as of 2026-08-11].
- Substantial future capital needs — Expenses expected to increase significantly as clinical trials advance; additional funding likely required [sec_mda · as of 2026-03-05].
- Clinical trial risks — Phase 1/2 trials ongoing; results uncertain and may affect program viability and stock price [sec_mda · as of 2026-03-05].
What to watch
- Progress and data readouts from ongoing Phase 1/2 clinical trials [sec_mda · as of 2026-03-05].
- Cash burn rate and any future capital raises or partnership updates [sec_mda · as of 2026-08-11].
- Regulatory developments and potential pivotal trial initiations [sec_mda · as of 2026-03-05].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Tango Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tango Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
76.2 months
D/E 0.05 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
1 upcoming, next in ~1097d
0 buys · 12 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$3.05B
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 13,300,620 | $278.2M |
| adage capital partners gp, l.l.c. | 12,809,485 | $268.0M |
| vanguard capital management llc | 10,322,862 | $216.0M |
| fmr llc | 9,905,919 | $207.2M |
| farallon capital management llc | 9,097,411 | $190.3M |
| blackrock, inc. | 8,748,045 | $183.0M |
| siren, l.l.c. | 5,657,105 | $118.3M |
| goldman sachs group inc | 5,076,392 | $106.2M |
| janus henderson group plc | 4,789,944 | $100.1M |
| state street corp | 4,651,894 | $97.3M |
Showing top 10 of 190 institutional holders of Tango Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 26.9%
- Days to cover
- 12.9
- Shares short
- 38,250,843
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TNGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tango Therapeutics, Inc.?
Tango Therapeutics, Inc. is a clinical-stage precision oncology company developing novel therapies targeting cancer vulnerabilities, with no approved products or product revenue to date.
What is Tango Therapeutics, Inc.'s lead drug candidate?
Tango Therapeutics, Inc.'s most advanced tracked candidate is TNG260 (Phase 1/Phase 2) for Non Small Cell Lung Cancer.
What is Tango Therapeutics, Inc.'s next catalyst?
Tango Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of A" — expected August 31, 2029.
Who is the CEO of Tango Therapeutics, Inc.?
Dr. Malte Peters M.D. is the chief executive officer of Tango Therapeutics, Inc. (TNGX).
Where is Tango Therapeutics, Inc. headquartered?
Tango Therapeutics, Inc. (TNGX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.